The acceptance of the BBI-940 IND enables Boundless to advance the program into a first-in-human clinical trial for patients with metastatic breast cancer, KOMODO-1 (Kinesin Oral Molecular Degrader ...
Dress codes have shifted dramatically since the pandemic, and style consultants say the pendulum now is swinging back.
A plan to slash Food and Drug Administration drug review times is raising alarms at the public health agency that's been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback